Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Burning Rock Biotech's gross profit for the
three
months ended in Mar. 2026 was $11.32 Mil. Burning Rock Biotech's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was $54.24 Mil.
Burning Rock Biotech (NAS:BNR) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Burning Rock Biotech had a gross margin of 72.26% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Burning Rock Biotech Gross Profit Related Terms
Burning Rock Biotech Gross Profit Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Burning Rock Biotech's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech Gross Profit vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Gross Profit distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $54.24 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Burning Rock Biotech (BNR) has a Gross Profit of $54.24 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Burning Rock Biotech and its competitors.
Is Burning Rock Biotech's Gross Profit too high?
Burning Rock Biotech's current Gross Profit is $54.24 Mil. Overall, Burning Rock Biotech has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Gross Profit compare to QUCY and IMDX?
Burning Rock Biotech's Gross Profit of $54.24 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Diagnostics & Research company?
A good Gross Profit depends on the Medical Diagnostics & Research industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Burning Rock Biotech and its competitors. Burning Rock Biotech's current Gross Profit is $54.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (BNR) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.45, compared to a current price of $9.67 — trading 29.8% above its estimated fair value. The current Gross Profit is $54.24 Mil. Burning Rock Biotech's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Burning Rock Biotech (BNR), the current Gross Profit is $54.24 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (BNR) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of $9.67 is trading 29.8% above its estimated GF Value™ of $7.45.
GuruFocus considers Burning Rock Biotech to be Modestly Overvalued.
Key valuation signals for BNR:
Gross Profit: $54.24 Mil
GF Value™: $7.45 vs. price of $9.67 (29.8% above fair value)
No single metric tells the full story. See the BNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
57GF Score
Get the complete analysis for BNR
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNR has been successfully added to your 
